GSK's diabetes drug set for European approval

LONDON Fri Jan 24, 2014 6:01am EST

LONDON Jan 24 (Reuters) - GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan.

Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca .

A positive recommendation for a drug by the European Medicines Agency is generally followed by a marketing authorisation by the European Commission. GSK said a final decision was anticipated later this quarter.

Last year regulators in the United States pushed back an approval decision on the drug until April 15.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.